Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jan;76(1):128-138.
doi: 10.1111/his.13989.

Vulval squamous cell carcinoma and its precursors

Naveena Singh  1 , C Blake Gilks  2
Affiliations
Review

Vulval squamous cell carcinoma and its precursors

Naveena Singh et al. Histopathology. 2020 Jan.

Abstract

Vulval squamous cell carcinoma (VSCC) can arise through two distinct pathways [human papillomavirus (HPV)-associated and HPV-independent], and these VSCC variants are recognised as different disease entities on the basis of different aetiologies, morphological features, molecular events during oncogenesis, precursor lesions, prognosis, and response to treatment. The precursor of HPV-associated VSCC, variously referred to as high-grade squamous intraepithelial lesion (HSIL) [vulvar intraepithelial neoplasia (VIN) 2/3] or usual-type VIN, is morphologically identical to the more common HSIL (cervical intraepithelial neoplasia 2/3) of the cervix. The precursor lesions of HPV-independent VSCC include differentiated VIN, differentiated exophytic vulvar intraepithelial lesion, and vulvar acanthosis with altered differentiation; these have been under-recognised by pathologists in the past, leading to delays in treatment. This review will discuss the recent advances in diagnostic surgical pathology of VSCC and its precursors, and how these diagnoses can impact on patient management.

Keywords: DEVIL; HSIL; VAAD; VIN; dVIN; squamous cell carcinoma; vulva.

PubMed Disclaimer

References

    1. SEER cancer stat facts: Vulvar cancer. Bethesda, MD: National Cancer Institute. Available at: https://seer.cancer.gov/statfacts/html/vulva.html
    1. Gatta G, Capocaccia R, Trama A, Martínez-García C; RARECARE Working Group. The burden of rare cancers in Europe. Adv. Exp. Med. Biol. 2010; 686; 285-303.
    1. Munoz J, Kurzrock R. Targeted therapy in rare cancers - adopting the orphans. Nat. Rev. Clin. Oncol. 2012; 9; 631-642.
    1. Bloss JD, Liao SY, Wilczynski SP et al. Clinical and histologic features of vulvar carcinomas analyzed for human papillomavirus status: evidence that squamous cell carcinoma of the vulva has more than one etiology. Hum. Pathol. 1991; 22; 711-718.
    1. Toki T, Kurman RJ, Park JS et al. Probable nonpapillomavirus etiology of squamous cell carcinoma of the vulva in older women: a clinicopathologic study using in situ hybridization and polymerase chain reaction. Int. J. Gynecol. Pathol. 1991; 10; 107-125.

LinkOut - more resources